Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Wang

Showing results (461-470 of 603) with videos related to

Pageof 61
Sort By:
Journal of Medicinal Chemistry|October 2, 2009
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationThorsten A Kirschberg, Mini Balakrishnan, Neil H Squires, et al.
Molecular Cancer|September 26, 2022
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphomaVivian Changying Jiang, Dapeng Hao, Preetesh Jain, et al.
Spine|September 22, 2025
Does Achievement of Ideal L1 Pelvic Angle with MIS Techniques in Adult Spinal Deformity Correction Lead to Better Outcomes?Ryan Khanna, Robert Eastlack, Gregory Mundis, et al.
Leukemia & Lymphoma|July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaQaiser Bashir, Nina Shah, Simrit Parmar, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptaseMichael L Mitchell, Jong Chan Son, Hongyan Guo, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Journal of Hematology & Oncology|June 3, 2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility studyM Kay Garcia, Lorenzo Cohen, Ying Guo, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat, Rima Saliba, Rupinderjit Thandi, et al.
Pageof 61

Showing results (461-470 of 603) with videos related to

Sort By:
Pageof 61
Journal of Medicinal Chemistry|October 2, 2009
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationThorsten A Kirschberg, Mini Balakrishnan, Neil H Squires, et al.
Molecular Cancer|September 26, 2022
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphomaVivian Changying Jiang, Dapeng Hao, Preetesh Jain, et al.
Spine|September 22, 2025
Does Achievement of Ideal L1 Pelvic Angle with MIS Techniques in Adult Spinal Deformity Correction Lead to Better Outcomes?Ryan Khanna, Robert Eastlack, Gregory Mundis, et al.
Leukemia & Lymphoma|July 26, 2011
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaQaiser Bashir, Nina Shah, Simrit Parmar, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptaseMichael L Mitchell, Jong Chan Son, Hongyan Guo, et al.
British Journal of Haematology|October 15, 2013
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphomaYasuhiro Oki, Jason R Westin, Francisco Vega, et al.
Journal of Hematology & Oncology|June 3, 2014
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility studyM Kay Garcia, Lorenzo Cohen, Ying Guo, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphomaAndre Goy, Anas Younes, Peter McLaughlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 20, 2009
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myelomaUday Popat, Rima Saliba, Rupinderjit Thandi, et al.
Pageof 61